This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
DAIC
MARCH 26, 2025
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
HCPLive
MAY 20, 2024
A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.
116 
HCPLive
FEBRUARY 12, 2025
Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.
120 
Medical Xpress - Cardiology
DECEMBER 19, 2023
Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
Medical Xpress - Cardiology
MARCH 7, 2025
Patients with chronic kidney disease (CKD) and heart failure have higher rates of inpatient dialysis initiation than those without heart failure, according to a study published online Feb. 18 in Mayo Clinic Proceedings.
Cardiovascular Diabetology
MARCH 21, 2025
Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.
Open Heart
OCTOBER 31, 2024
Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers.
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.
105 
DAIC
JULY 30, 2024
This study by Fujita Health University researchers revealed that kidney function, considered in terms of estimated glomerular filtration rate (eGFR), can be used as a predictor for SCD in patients with congestive heart failure. During the follow-up period, 198 of these patients suffered from SCD.
Circulation
SEPTEMBER 10, 2024
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions.
HCPLive
MARCH 26, 2025
Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.
Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
Science Daily - Heart Disease
FEBRUARY 14, 2025
New research shows sotagliflozin is the only drug in its class to demonstrate these results.
104 
HCPLive
SEPTEMBER 26, 2024
Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.
105 
Science Daily - Heart Disease
DECEMBER 16, 2024
atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant complications associated with this condition include ischemic stroke, heart failure, myocardial infarction, chronic kidney disease, dementia and mortality.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
HCPLive
NOVEMBER 11, 2024
Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).
CardiacWire
OCTOBER 6, 2024
Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. The post Finerenone’s Early Heart Failure Impact appeared first on Cardiac Wire. And with a new drug, knowing which patients to target is a good way to start.
Frontiers in Cardiovascular Medicine
DECEMBER 18, 2023
Chronic kidney disease coexists in up to 40%–50% of patients with chronic heart failure cases. There are guidelines for patients with heart failure and chronic kidney disease separately, but they do not specifically address patients with concomitant heart failure and kidney disease.
93 
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Journal of the American Heart Association
FEBRUARY 24, 2025
Journal of the American Heart Association, Ahead of Print.
European Journal of Heart Failure
OCTOBER 18, 2023
Mineralocorticoid receptor antagonist (MRA) use in severe chronic kidney disease and heart failure with reduced ejection fraction (HFrEF). Methods and results We analysed patients with HFrEF (ejection fraction <40%), not on dialysis, from the Swedish Heart Failure Registry.
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.
98 
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.
American College of Cardiology
FEBRUARY 5, 2024
Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
75 
Dr. Paddy Barrett
NOVEMBER 1, 2024
Death from heart disease: 51% reduction in risk. Heart Failure: 69% reduction in risk. Kidney Disease: 42% reduction in risk. Death from any cause: 53% reduction in risk. Cancer deaths: 43% reduction in risk. High Blood Pressure: 37% reduction in risk. Dementia: 64% reduction in risk. Let me be clear.
119 
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. a If patients were receiving both types of diuretics at baseline, they were included in both subgroups. Patients were analysed by baseline diuretic use (yes/no) and type of diuretic (loop or thiazide).
Cardiovascular Diabetology
AUGUST 6, 2024
Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Furthermore, compared with other GLD, the use of cardioprotective GLD was more common in patients with a less frequent history of heart failure (5.0%
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
81 
Journal of the American Heart Association
DECEMBER 24, 2024
Journal of the American Heart Association, Ahead of Print. The index date was the first CKD stage 3b/4 diagnosis with 1 hyperkalemia diagnosis and 1 serum potassium >5.0 mmol/L in the preceding 12 months (baseline) for patients with hyperkalemia and a randomly selected CKD stage 3b/4 diagnosis for controls.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Open Heart
APRIL 24, 2024
Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.
Open Heart
JUNE 1, 2022
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heart failure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE).
MIBHS
FEBRUARY 15, 2025
Secondary hypertension : This type results from an underlying condition such as kidney disease, hormonal disorders, or the use of certain medications. The Link Between High Blood Pressure and Heart Health Your heart and blood vessels form a complex network that ensures oxygen and nutrients reach every part of your body.
Journal of the American Heart Association
JANUARY 12, 2024
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness.
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001).
European Journal of Heart Failure
JANUARY 20, 2025
The predictive ability of different risk scores developed and validated to predict the risk of mortality in patients with heart failure in the HELP-HF cohort is reported and compared based on their areas under the curve.
Circulation
NOVEMBER 11, 2024
A 35-year-old gravida 1, para 0 with biventricular heart failure (LVEF 25%), nonischemic cardiomyopathy, history stroke, history of left ventricular thrombus, class III obesity, and chronic kidney disease who had been followed by Cardio-Obstetrics throughout her pregnancy presented at 34 weeks gestation for planned induction of labor.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content